La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ApicHope Pharmaceutical Croissance future
Future contrôle des critères 4/6
ApicHope Pharmaceutical is forecast to grow earnings and revenue by 26.4% and 16% per annum respectively. EPS is expected to grow by 25.6% per annum. Return on equity is forecast to be 11.1% in 3 years.
Informations clés
26.4%
Taux de croissance des bénéfices
25.6%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 18.8% |
| Taux de croissance des recettes | 16.0% |
| Rendement futur des capitaux propres | 11.1% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 31 Jul 2024 |
Mises à jour récentes de la croissance future
Recent updates
Does ApicHope Pharmaceutical (SZSE:300723) Have A Healthy Balance Sheet?
Jun 27
ApicHope Pharmaceutical (SZSE:300723) Is Paying Out A Larger Dividend Than Last Year
May 27ApicHope Pharmaceutical's (SZSE:300723) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Bearish: Analysts Just Cut Their ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Revenue and EPS estimates
May 02ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet
Mar 15Market Participants Recognise ApicHope Pharmaceutical Co., Ltd's (SZSE:300723) Earnings
Feb 27Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 3,674 | 394 | N/A | 677 | 3 |
| 12/31/2025 | 3,473 | 423 | N/A | 623 | 4 |
| 12/31/2024 | 2,777 | 333 | N/A | 574 | 3 |
| 3/31/2024 | 2,410 | 174 | 135 | 480 | N/A |
| 12/31/2023 | 2,503 | 185 | 124 | 458 | N/A |
| 9/30/2023 | 2,515 | 307 | 119 | 416 | N/A |
| 6/30/2023 | 2,641 | 341 | 123 | 511 | N/A |
| 3/31/2023 | 2,480 | 322 | -21 | 480 | N/A |
| 1/1/2023 | 2,280 | 291 | -130 | 476 | N/A |
| 9/30/2022 | 2,161 | 285 | -153 | 511 | N/A |
| 6/30/2022 | 2,151 | 344 | -157 | 540 | N/A |
| 3/31/2022 | 2,200 | 319 | -176 | 455 | N/A |
| 12/31/2021 | 2,199 | 307 | -123 | 438 | N/A |
| 9/30/2021 | 2,135 | 317 | -133 | 388 | N/A |
| 6/30/2021 | 1,978 | 263 | -163 | 279 | N/A |
| 3/31/2021 | 1,851 | 250 | -63 | 341 | N/A |
| 12/31/2020 | 1,675 | 226 | -39 | 275 | N/A |
| 9/30/2020 | 1,640 | 173 | -51 | 201 | N/A |
| 6/30/2020 | 1,515 | 117 | 78 | 249 | N/A |
| 3/31/2020 | 1,641 | 138 | 28 | 144 | N/A |
| 12/31/2019 | 1,637 | 144 | 175 | 281 | N/A |
| 9/30/2019 | 1,537 | 243 | 223 | 301 | N/A |
| 6/30/2019 | 1,435 | 234 | 169 | 275 | N/A |
| 3/31/2019 | 1,395 | 219 | 24 | 297 | N/A |
| 12/31/2018 | 1,430 | 208 | -18 | 239 | N/A |
| 9/30/2018 | 1,426 | 180 | 23 | 263 | N/A |
| 6/30/2018 | 1,477 | 167 | -10 | 185 | N/A |
| 3/31/2018 | 1,467 | 166 | 156 | 186 | N/A |
| 12/31/2017 | 1,380 | 157 | N/A | 158 | N/A |
| 9/30/2017 | 1,399 | 156 | N/A | 109 | N/A |
| 12/31/2016 | 1,251 | 137 | N/A | 146 | N/A |
| 12/31/2015 | 1,028 | 60 | N/A | 35 | N/A |
| 12/31/2014 | 793 | 40 | N/A | 9 | N/A |
| 12/31/2013 | 508 | 33 | N/A | 136 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 300723's forecast earnings growth (26.4% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 300723's earnings (26.4% per year) are forecast to grow faster than the CN market (21.9% per year).
Croissance élevée des bénéfices: 300723's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 300723's revenue (16% per year) is forecast to grow faster than the CN market (13.4% per year).
Croissance élevée des revenus: 300723's revenue (16% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 300723's Return on Equity is forecast to be low in 3 years time (11.1%).